Author/Editor     Gužič-Salobir, Barbara
Title     Dejavniki tveganja za aterosklerozo pri hormonskem nadomestnem zdravljenju v pomenopavzi
Type     monografija
Place     Ljubljana
Publisher     Medicinska fakulteta
Publication year     2002
Volume     str. 62
Language     slo
Abstract     Background: Menopause is associated with increased risk for coronary heart disease. Large scale epidemiological studies suggest that hormone replacement therapy (HRT) reduces cardiovascular events in postmenopausal women. Endothelial dysfunction is an early phenomenon in atherosclerosis. In recent years, the effects of HRT on endothelial function have been extensively investigated. It has been shown that HRT improves endothelial function. The aim of our study was to investigate in a randomized, double blind, placebo controlled trial the effects of continuous combined HRT on different cardiovascular risk factors in healthy postmenopausal women. Subjects and methods: The study was randomized, double blind, and placebo controlled. Among 61 healthy postmenopausal women, 31 were randomized to receive oral continuous combined HRT (estradiol 2 mg and norethisterone acetate 1 mg per day) and 30 to receive placebo. A general physical examination and blood sampling were performed at baseline, after 3 and after 6 months of treatment. In blood samples, estradiol, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a), blood glucose, insulin, soluble cell adhesion molecules: E-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), P-selectin; markers of inflammation: C-reactive protein (CRP), serum amyloid A, fibrinogen, interleukin-6, tumor necrosis factor-alpha; and parameters of coagulation and fibrinolytic systems: antithrombin III activity, protein C activity, prothrombin fragment 1+2 (F1+2) antigen, thromin-antithrombin III (TAT) complex antigen, plasminogen activator inhibitor-1 (PAI-1) antigen, tissue-type plasminogen activator (t-PA) antigen and euglobulin clot lysis time (ECLT) were determined. (Abstract truncated at 2000 characters).
Descriptors     POSTMENOPAUSE
ESTROGEN REPLACEMENT THERAPY
ATHEROSCLEROSIS
BRACHIAL ARTERY
VASODILATION
ESTRADIOL
CHOLESTEROL
LIPOPROTEINS, HDL CHOLESTEROL
LIPOPROTEINS, LDL CHOLESTEROL
TRIGLYCERIDES
LIPOPROTEIN(A)
BLOOD GLUCOSE
INSULIN
FIBRINOLYSIS
E-SELECTIN
P-SELECTIN
TUMOR NECROSIS FACTOR
INTERCELLULAR ADHESION MOLECULE-1
VASCULAR CELL ADHESION MOLECULE-1
C-REACTIVE PROTEIN
AMYLOID PROTEIN SAA
INTERLEUKIN-6